|
1
|
Orr GA, Verdier-Pinard P, McDaid H and
Horwitz SB: Mechanisms of Taxol resistance related to microtubules.
Oncogene. 22:7280–7295. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marcus AI, Peters U, Thomas SL, et al:
Mitotic kinesin inhibitors induce mitotic arrest and cell death in
Taxol-resistant and -sensitive cancer cells. J Biol Chem.
280:11569–11577. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang YI, Lee KT, Park HJ, et al:
Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer
cells through downregulation of the Akt and NFκB pathway.
Carcinogenesis. 33:2488–2498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lai D, Ho KC, Hao Y and Yang X: Taxol
resistance in breast cancer cells is mediated by the hippo pathway
component TAZ and its downstream transcriptional targets Cyr61 and
CTGF. Cancer Res. 71:2728–2738. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ledwitch K, Ogburn R, Cox J, et al: Taxol:
efficacy against oral squamous cell carcinoma. Mini Rev Med Chem.
13:509–521. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu R, Sato N, Yanai K, et al: Enhancement
of paclitaxel-induced apoptosis by inhibition of mitogen-activated
protein kinase pathway in colon cancer cells. Anticancer Res.
29:261–270. 2009.PubMed/NCBI
|
|
7
|
Groen HJ, Fokkema E, Biesma B, et al:
Paclitaxel and carboplatin in the treatment of small-cell lung
cancer patients resistant to cyclophosphamide, doxorubicin, and
etoposide: a non-cross-resistant schedule. J Clin Oncol.
17:927–932. 1999.PubMed/NCBI
|
|
8
|
González Cao M, Viteri S, Garrán C, et al:
Response of resistant melanoma to a combination of weekly
paclitaxel and bevacizumab. Clin Transl Oncol. 9:119–120. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yusuf RZ, Duan Z, Lamendola DE, Penson RT
and Seiden MV: Paclitaxel resistance: molecular mechanisms and
pharmacologic manipulation. Curr Cancer Drug Targets. 3:1–19. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gottesman MM and Pastan I: Biochemistry of
multidrug resistance mediated by the multidrug transporter. Annu
Rev Biochem. 62:385–427. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kavallaris M, Kuo DY, Burkhart CA, et al:
Taxol-resistant epithelial ovarian tumors are associated with
altered expression of specific beta-tubulin isotypes. J Clin
Invest. 100:1282–1293. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Panda D, Miller HP, Banerjee A, Ludueña RF
and Wilson L: Microtubule dynamics in vitro are regulated by the
tubulin isotype composition. Proc Natl Acad Sci USA.
91:11358–11362. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Martello LA, Verdier-Pinard P, Shen HJ, et
al: Elevated levels of microtubule destabilizing factors in a
Taxol-resistant/dependent A549 cell line with an alpha-tubulin
mutation. Cancer Res. 63:1207–1213. 2003.PubMed/NCBI
|
|
14
|
Gonçalves A, Braguer D, Kamath K, et al:
Resistance to Taxol in lung cancer cells associated with increased
microtubule dynamics. Proc Natl Acad Sci USA. 98:11737–11742. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tan M, Jing T, Lan KH, et al:
Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits
p34(Cdc2) activation and is involved in resistance to taxol-induced
apoptosis. Mol Cell. 9:993–1004. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu J, Tan M, Huang WC, et al: Mitotic
deregulation by survivin in ErbB2-overexpressing breast cancer
cells contributes to Taxol resistance. Clin Cancer Res.
15:1326–1334. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Warburg O: On respiratory impairment in
cancer cells. Science. 124:269–270. 1956.PubMed/NCBI
|
|
18
|
Jang M, Kim SS and Lee J: Cancer cell
metabolism: implications for therapeutic targets. Exp Mol Med.
45:e452013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saed GM, Fletcher NM, Jiang ZL, et al:
Dichloroacetate induces apoptosis of epithelial ovarian cancer
cells through a mechanism involving modulation of oxidative stress.
Reprod Sci. 18:1253–1261. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sutendra G and Michelakis ED: Pyruvate
dehydrogenase kinase as a novel therapeutic target in oncology.
Front Oncol. 3:382013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Michelakis ED, Webster L and Mackey JR:
Dichloroacetate (DCA) as a potential metabolic-targeting therapy
for cancer. Br J Cancer. 99:989–994. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fujiwara S, Kawano Y, Yuki H, et al: PDK1
inhibition is a novel therapeutic target in multiple myeloma. Br J
Cancer. 108:170–178. 2013.PubMed/NCBI
|
|
23
|
Zhao Y, Butler EB and Tan M: Targeting
cellular metabolism to improve cancer therapeutics. Cell Death Dis.
4:e5322013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fulda S and Debatin KM: HIF-1-regulated
glucose metabolism: a key to apoptosis resistance? Cell Cycle.
6:790–792. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou M, Zhao Y, Ding Y, et al: Warburg
effect in chemosensitivity: targeting lactate dehydrogenase-A
re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer.
9:332010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bryan M, Pulte ED, Toomey KC, et al: A
pilot phase II trial of all-trans retinoic acid (Vesanoid) and
paclitaxel (Taxol) in patients with recurrent or metastatic breast
cancer. Invest New Drugs. 29:1482–1487. 2011. View Article : Google Scholar
|
|
27
|
Ishibashi M, Nakayama K, Yeasmin S, et al:
A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a
potential target for Taxol resistance in ovarian cancer. Clin
Cancer Res. 14:3149–3155. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang X, Pan L, Mao N, et al: Cell-cycle
synchronization reverses Taxol resistance of human ovarian cancer
cell lines. Cancer Cell Int. 13:772013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ding Y, Liu Z, Desai S, et al: Receptor
tyrosine kinase ErbB2 translocates into mitochondria and regulates
cellular metabolism. Nat Commun. 3:12712012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zheng J: Energy metabolism of cancer:
Glycolysis versus oxidative phosphorylation (Review). Oncol Lett.
4:1151–1157. 2012.PubMed/NCBI
|
|
31
|
Elstrom RL, Bauer DE, Buzzai M, et al: Akt
stimulates aerobic glycolysis in cancer cells. Cancer Res.
64:3892–3899. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fan Y, Dickman KG and Zong WX: Akt and
c-Myc differentially activate cellular metabolic programs and prime
cells to bioenergetic inhibition. J Biol Chem. 285:7324–7333. 2010.
View Article : Google Scholar :
|
|
33
|
Kim JW, Tchernyshyov I, Semenza GL and
Dang CV: HIF-1-mediated expression of pyruvate dehydrogenase
kinase: a metabolic switch required for cellular adaptation to
hypoxia. Cell Metab. 3:177–185. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Madhok BM, Yeluri S, Perry SL, Hughes TA
and Jayne DG: Dichloroacetate induces apoptosis and cell-cycle
arrest in colorectal cancer cells. Br J Cancer. 102:1746–1752.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Michelakis ED, Sutendra G, Dromparis P, et
al: Metabolic modulation of glioblastoma with dichloroacetate. Sci
Transl Med. 2:31ra342010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kato M, Li J, Chuang JL and Chuang DT:
Distinct structural mechanisms for inhibition of pyruvate
dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and
radicicol. Structure. 15:992–1004. 2007. View Article : Google Scholar : PubMed/NCBI
|
